Literature DB >> 10438889

Inhibition of Borna disease virus replication by ribavirin.

I Jordan1, T Briese, D R Averett, W I Lipkin.   

Abstract

The guanosine analogue ribavirin was tested for antiviral activity in two neural cell lines, human oligodendrocytes and rat glia, against Borna disease virus (BDV) strains V and He/80. Ribavirin treatment resulted in lower levels of virus and viral transcripts within 12 h. Addition of guanosine but not adenosine resulted in a profound reduction of the ribavirin effect. Ribavirin appears to be an effective antiviral agent for treatment of BDV infection in vitro. A likely mechanism for its activity is reduction of the intracellular GTP pool, resulting in inhibition of transcription and capping of BDV mRNAs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438889      PMCID: PMC104326     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Authors:  S Khakoo; P Glue; L Grellier; B Wells; A Bell; C Dash; I Murray-Lyon; D Lypnyj; B Flannery; K Walters; G M Dusheiko
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

2.  Evolution of the immune response in the central nervous system following infection with Borna disease virus.

Authors:  C G Hatalski; W F Hickey; W I Lipkin
Journal:  J Neuroimmunol       Date:  1998-10-01       Impact factor: 3.478

3.  Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.

Authors:  B Eriksson; E Helgstrand; N G Johansson; A Larsson; A Misiorny; J O Norén; L Philipson; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

4.  A new class of synthetic nucleoside analogues with broad-spectrum antiviral properties.

Authors:  P Prusiner; M Sundaralingam
Journal:  Nat New Biol       Date:  1973-07-25

5.  Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

Authors:  R C Tam; B Pai; J Bard; C Lim; D R Averett; U T Phan; T Milovanovic
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

6.  Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression.

Authors:  L Bode; D E Dietrich; R Stoyloff; H M Emrich; H Ludwig
Journal:  Lancet       Date:  1997-01-18       Impact factor: 79.321

7.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

8.  Effect of immune priming on Borna disease.

Authors:  A J Lewis; J L Whitton; C G Hatalski; H Weissenböck; W I Lipkin
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  [Natural borna virus infection in rabbits].

Authors:  A Metzler; F Ehrensperger; R Wyler
Journal:  Zentralbl Veterinarmed B       Date:  1978-03

10.  Behavior alterations in tree shrews (Tupaia glis, Diard 1820) induced by Borna disease virus.

Authors:  H Sprankel; K Richarz; H Ludwig; R Rott
Journal:  Med Microbiol Immunol       Date:  1978-05-26       Impact factor: 3.402

View more
  19 in total

1.  Mechanism of action of T-705 against influenza virus.

Authors:  Yousuke Furuta; Kazumi Takahashi; Masako Kuno-Maekawa; Hidehiro Sangawa; Sayuri Uehara; Kyo Kozaki; Nobuhiko Nomura; Hiroyuki Egawa; Kimiyasu Shiraki
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 2.  Borna disease virus and human disease.

Authors:  K M Carbone
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

3. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

4.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.

Authors:  Utthara Nayar; Jouliana Sadek; Jonathan Reichel; Denise Hernandez-Hopkins; Gunkut Akar; Peter J Barelli; Michelle A Sahai; Hufeng Zhou; Jennifer Totonchy; David Jayabalan; Ruben Niesvizky; Ilaria Guasparri; Duane Hassane; Yifang Liu; Shizuko Sei; Robert H Shoemaker; J David Warren; Olivier Elemento; Kenneth M Kaye; Ethel Cesarman
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

Review 5.  Avian bornavirus associated with fatal disease in psittacine birds.

Authors:  Peter Staeheli; Monika Rinder; Bernd Kaspers
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

6.  MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells.

Authors:  O Planz; S Pleschka; S Ludwig
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Mechanism of the antiviral action of 1-beta-D-arabinofuranosylcytosine on Borna disease virus.

Authors:  Romain Volmer; Jeffrey J Bajramovic; Urs Schneider; Sandra Ufano; Sylvie Pochet; Daniel Gonzalez-Dunia
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats.

Authors:  Marylou V Solbrig; Yijun Fan; Neal Hermanowicz; Maria Grazia Morgese; Andrea Giuffrida
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

9.  Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.

Authors:  Nirav R Shah; Amanda Sunderland; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

10.  Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica.

Authors:  Fumitaka Shimizu; Kristin L Schaller; Gregory P Owens; Anne C Cotleur; Debra Kellner; Yukio Takeshita; Birgit Obermeier; Thomas J Kryzer; Yasuteru Sano; Takashi Kanda; Vanda A Lennon; Richard M Ransohoff; Jeffrey L Bennett
Journal:  Sci Transl Med       Date:  2017-07-05       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.